Health Canada has approved ZINBRYTA™ (daclizumab beta), a new once-monthly, self administered, subcutaneous treatment for adult patients with active relapsing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE